Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial

Achard, Vérane; Jaccard, Maud; Vanhoutte, F.; Heikkilä, Reino; Dirix, Piet; Liefhooghe, Nick; Otte, F.; Gómez-Iturriaga, A.; Berghen, Charlien; Shelan, Mohamed; Conde-Moreno, Antonio José; Campos, F. López; Papachristofilou, Alexandros; Gückenberger, Matthias; Meersschout, Sabine; Putora, Paul Martin; Zwahlen, Daniel R.; Couñago, Felipe; Scorsetti, Marta; Eito, C.; Barrado, M.; Zapatero, A.; Muto, Paolo; Voorde, Lien Van De; Lamanna, Giorgio; Koutsouvelis, Nikolaos; Dipasquale, G.; Ost, Piet; Zilli, Thomas

doi:10.1016/j.radonc.2022.04.020

Cited by 5 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limitations of the present work include the lack of a correlation between the volumes and the dosimetric data, including the potential effect on the surrounding organs at risk, though our previous work showed that despite the volume differences, doses constraints were respected for all plans. 4 However, this study provides quantitative and qualitative analyses on real-world delineation of pelvic lymph node regions using specific contouring recommendations similar to the NRG 2020 guidelines. 12 …”

Section: Discussionmentioning

confidence: 99%

“…Anonymized Digital Imaging and Communications in Medicine images of the CT and PET/CT scan of this patient were sent to the participating centers with the instructions to delineate the volumes and to perform treatment planning for each arm according to the trial protocol. 4 Different center-specific treatment planning systems were used for clinical target volume (CTV) delineation.…”

Section: Methodsmentioning

confidence: 99%

“…Twenty-four centers completed the quality assurance of the trial, and assessment of outlining and treatment planning through this BC was conducted. 4 Structures and treatment planning were evaluated as unacceptable variation, acceptable variation, or per protocol according to the Global Harmonization Group Guidelines. 5 Per protocol and acceptable variation in delineation/dosimetry of the BC were communicated to the centers, which were activated for patient's inclusion.…”

Section: Introductionmentioning

confidence: 99%

“…Repeated BC resulted in an improved acceptable contouring and planning and adherence to the protocol. 4 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial

Lorton¹,

Achard²,

Koutsouvelis³

et al. 2023

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Repeated BC resulted in an improved acceptable contouring and planning and adherence to the protocol. 4 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial

Lorton¹,

Achard²,

Koutsouvelis³

et al. 2023

Advances in Radiation Oncology

Self Cite

View full text Add to dashboard Cite

“…It will be important to include modern anatomic and metabolic imaging as part of staging. This will help optimize targets of therapy and identify patients in need of extended volume therapy due to oligometastatic disease [52][53][54][55].…”

Section: Genitourinarymentioning

confidence: 99%

Modern Clinical Trials in Radiation Oncology

Fitzgerald¹,

Laurie²,

Iandoli³

et al. 2023

Frontiers in Clinical Trials

View full text Add to dashboard Cite

Clinical trials in radiation oncology have improved our translational science and patient care. All patients referred to departments of radiation oncology can be invited to participate in a clinical trial with multiple venues. Study endpoints can include intradepartmental endpoints to improve workflow and patient access as well as interdepartmental clinical translational trials that include the National Clinical Trials Network (NCTN) and industry. The quality of the trial is important to trial outcome and influences interpretation of the results of the study and how the results can be applied to patient care moving forward. Clinical trials in radiation oncology to date have accomplished much, however many important questions remain as patient care matures and systemic therapies become more sophisticated and associated with specific biomarkers and cellular expression products. In this chapter we review the history of clinical trials in radiation oncology and review the current status of the structure of quality assurance in clinical trials. We will review unanswered questions and areas to study in each disease area and how to design strategy for trials to address modern unmet needs in our discipline.

show abstract

PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

Ost,

Siva,

Brabrand

et al. 2024

European Urology Oncology

View full text Add to dashboard Cite

Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial

Cited by 5 publications

References 41 publications

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial

Modern Clinical Trials in Radiation Oncology

PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial

Contact Info

Product

Resources

About